| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/12/2011 | US7977316 Prevention and treatment of amyloidogenic diseases |
| 07/12/2011 | US7977315 prenylation enzyme inhibitors such as 5,9,13-trimethyl-2-nitrotetradeca-2,8,12-triene, used as anticarcinogenic or antitumor agents |
| 07/12/2011 | US7977066 Method for preparing tryptophan rich peptides |
| 07/12/2011 | US7977065 Yeast strains autonomously producing steroids |
| 07/12/2011 | US7977059 17867, a novel human aminopeptidase |
| 07/12/2011 | US7976846 Stress protein complex; a grp170 polypeptide and an immunogenic polypeptide; antitumor |
| 07/12/2011 | US7976843 Method for screening peptides for use in immunotherapy |
| 07/12/2011 | US7976841 Anti TfR antibody |
| 07/12/2011 | US7976840 Use of anti-GL50 antibodies for the downmodulation of an immune response |
| 07/12/2011 | US7976835 Methods and compositions for preventing and treating solid tumors |
| 07/12/2011 | CA2669128C Treatment for multiple myeloma |
| 07/12/2011 | CA2663401C Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
| 07/12/2011 | CA2651363C Triazolopyrazine derivatives useful as anti-cancer agents |
| 07/12/2011 | CA2582479C Benzoimidazole derivatives useful as antiproliferative agents |
| 07/12/2011 | CA2555435C Alpha-emitting hydroxyapatite particles |
| 07/12/2011 | CA2524394C Novel benzodiazepine compounds, compositions and uses thereof |
| 07/12/2011 | CA2503451C Heterocyclic compounds and antitumor agent comprising the same as effective component |
| 07/12/2011 | CA2499756C Imidazopyrazines as cyclin dependent kinase inhibitors |
| 07/12/2011 | CA2486738C Method for identifying immunoreactive peptides |
| 07/12/2011 | CA2481767C Severe sepsis preventive therapeutic agent |
| 07/12/2011 | CA2480162C Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 |
| 07/12/2011 | CA2470078C Selective urokinase inhibitors |
| 07/12/2011 | CA2463616C Affinity enhancement agents |
| 07/12/2011 | CA2463505C Low-calcemic oxime analogs of 1.alpha.,25-dihydroxy vitamin d3 |
| 07/12/2011 | CA2458455C Pharmaceutical compositions comprising colloidal silicon dioxide |
| 07/12/2011 | CA2457528C Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina) |
| 07/12/2011 | CA2449150C Tricyclic compounds useful as angiotensin ii agonists |
| 07/12/2011 | CA2440610C Induction of tumor immunity by variants of folate binding protein |
| 07/12/2011 | CA2435611C Alpha-amino-n-hydroxy-acetamide derivatives |
| 07/12/2011 | CA2431617C 7-heterocyclyl quinoline and thieno[2,3-b]pyridine derivatives useful as antagonists of gonadotropin releasing hormone |
| 07/12/2011 | CA2417858C Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/12/2011 | CA2408956C Method and form of a drug delivery device,such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 07/12/2011 | CA2397347C Factor vii or viia-like molecules |
| 07/12/2011 | CA2396744C Synthetic lipid-a analogs and uses thereof |
| 07/12/2011 | CA2393200C Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 07/12/2011 | CA2373972C Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 07/12/2011 | CA2362527C A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer |
| 07/12/2011 | CA2352286C Intracellular targeted delivery of compounds by 70 kd heat shock protein |
| 07/12/2011 | CA2341336C Elongase genes and uses thereof |
| 07/12/2011 | CA2279971C Androgen synthesis inhibitors |
| 07/12/2011 | CA2277850C Genetic alterations associated with cancer |
| 07/12/2011 | CA2162262C Methods for treating muscle diseases and disorders |
| 07/07/2011 | WO2011082400A2 Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| 07/07/2011 | WO2011082345A2 Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof |
| 07/07/2011 | WO2011082290A2 Formulations from natural products, turmeric, and aspirin |
| 07/07/2011 | WO2011082273A2 Substituted pyrrolo-aminopyrimidine compounds |
| 07/07/2011 | WO2011082267A2 Substituted triazolo-pyrazine compounds |
| 07/07/2011 | WO2011082266A2 Substituted heterocyclic compounds |
| 07/07/2011 | WO2011082245A2 Metalloenzyme inhibitor compounds |
| 07/07/2011 | WO2011082187A1 Methods for modulating a pdgf-aa mediated biological response |
| 07/07/2011 | WO2011081971A2 Egfr/vegfr dual modulators and methods of using |
| 07/07/2011 | WO2011081970A2 MOLECULES RELATED hERG Ion CHANNELS AND THE USE THEREOF |
| 07/07/2011 | WO2011081523A1 Interferon analogs |
| 07/07/2011 | WO2011081465A2 Pharmaceutical composition for suppression of vascularization |
| 07/07/2011 | WO2011081443A2 Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof |
| 07/07/2011 | WO2011081430A2 Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy |
| 07/07/2011 | WO2011081415A2 Sirna for inhibiting c-met expression and an anti-cancer composition comprising the same |
| 07/07/2011 | WO2011081408A2 Imatinib dichloroacetate and anti-cancer agent comprising the same |
| 07/07/2011 | WO2011081373A2 Method for preparing highly pure anhydrous crystalline docetaxel |
| 07/07/2011 | WO2011081294A2 Recombinant adenovirus having anti-angiogenesis activity |
| 07/07/2011 | WO2011081229A1 Pharmaceutical composition for inhibiting angiogenesis |
| 07/07/2011 | WO2011081205A1 1,3,4-oxadiazole-2-carboxamide compound |
| 07/07/2011 | WO2011081173A1 Tetracyclic compound |
| 07/07/2011 | WO2011081164A1 Anti-cd27 antibody |
| 07/07/2011 | WO2011080796A1 Anti-cdh3 antibodies and uses thereof |
| 07/07/2011 | WO2011080510A1 Tricyclic compounds for use as kinase inhibitors |
| 07/07/2011 | WO2011080401A1 Receptor tyrosine kinase-binding compositions |
| 07/07/2011 | WO2011080259A1 Lipopeptide- and lipoprotein-conjugates and its use |
| 07/07/2011 | WO2011079804A1 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
| 07/07/2011 | WO2011079501A1 Prodrug based on cytarabine structure as well as synthesizing method and application thereof |
| 07/07/2011 | WO2011079494A1 Halogenated dideoxy saccharide derivatives, preparation method and use thereof |
| 07/07/2011 | WO2011079431A1 Fusion protein with telomerase inhibiting activity, preparation method and use thereof |
| 07/07/2011 | WO2011058423A3 Identification and characterization of natural chemical entities by liquid chromatography and mass spectrometry lc-ms/ms and uses thereof |
| 07/07/2011 | WO2011052883A9 Method for activating a natural killer cell by adjusting the expression of the socs2 gene |
| 07/07/2011 | WO2011045080A3 Monoclonal antibodies to progastrin and their uses |
| 07/07/2011 | WO2011036183A3 Anti-cd33 antibodies and use thereof for immunotargeting in treating cd33-associated illnesses |
| 07/07/2011 | WO2011032161A8 Vaccines directed to langerhans cells |
| 07/07/2011 | WO2011031561A3 Nucleic acid molecules and uses thereof |
| 07/07/2011 | WO2011028800A3 Treatment of cognitive dysfunction with gangliosides |
| 07/07/2011 | WO2011018636A3 Photochemical internalization method |
| 07/07/2011 | WO2011018635A3 Photosensitizing compositions |
| 07/07/2011 | WO2010136766A3 Use of nlee for the treatment of autoimmune and inflammatory disorders, targetting nf - kappa b |
| 07/07/2011 | WO2010136168A3 Continuous administration of cilengitide in cancer treatments |
| 07/07/2011 | WO2010111406A3 Purine derivatives useful as anti - cancer agents |
| 07/07/2011 | WO2010057275A8 Cyclic peptides and uses thereof |
| 07/07/2011 | US20110167512 Hybrid artichoke variety nun 4006 ar |
| 07/07/2011 | US20110166548 Drug releasing coatings for medical devices |
| 07/07/2011 | US20110166545 Apoptosis-inducing agent for prostate cancer cells |
| 07/07/2011 | US20110166409 Egfr and pten gene alterations predicts survival in patients with brain tumors |
| 07/07/2011 | US20110166320 Somatostatin analogues |
| 07/07/2011 | US20110166223 Methods of inhibiting fgfr3 signaling |
| 07/07/2011 | US20110166219 Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin |
| 07/07/2011 | US20110166218 Methods for micronization of hydrophobic drugs |
| 07/07/2011 | US20110166216 Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma |
| 07/07/2011 | US20110166214 Methods and compositions for delivery of taxanes in stable oil-in-water emulsions |
| 07/07/2011 | US20110166204 Oligonucleotides targeting human endogenous retrovirus 9 (erv-9) long terminal repeat (ltr) and methods of use |
| 07/07/2011 | US20110166201 Mirnas as therapeutic targets in cancer |
| 07/07/2011 | US20110166200 Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer |
| 07/07/2011 | US20110166199 RNAi COMPOUND TARGETED TO THROMBOSPONDIN-1 AND APPLICATIONS THEREOF |
| 07/07/2011 | US20110166191 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer |